Suggestions
Elli Kaplan
Co-founder and CEO
Elli Kaplan is a seasoned professional with two decades of experience in both the public and private sectors. She is the Co-founder and CEO of Neurotrack, a digital health company focusing on developing a digital cognitive assessment test for early and effective evaluation of individuals at risk for cognitive decline. Her work aims to advance research and treatment for cognitive diseases, notably Alzheimer’s, and enhance overall cognitive health.
Elli Kaplan's educational background includes an MBA from Harvard Business School and a BA in Politics and International Relations from Mount Holyoke College, where she was also part of the Honors Society.
Throughout her career, Elli has held various significant positions such as Health Innovators Fellow at The Aspen Institute, Fellow at Rock Health, COO at Flashpoint at Georgia Tech, Vice President of Business Development at Activate3D, and Executive Director at Peachtree Corridor Taskforce.
Prior to her current role at Neurotrack, Elli Kaplan gained valuable experience working at renowned organizations such as AIG Capital Partners, Goldman Sachs, the United Nations Development Programme, the U.S. Department of Treasury, the U.S. Department of State, and The White House, where she served as a Special Assistant in different capacities.
From her extensive professional journey to her innovative work at Neurotrack, Elli Kaplan continues to make strides in the field of cognitive health, combining her expertise in business development, public policy, and digital health technology to drive meaningful change and advancements in the healthcare industry.
Highlights
We’ve never felt more hopeful about treatment possibilities. If you didn’t catch it last week, check out the latest CBS 60 Minutes segment about the work Dr. Ali R. Rezai is doing to slow the progression of Alzheimer’s by using targeted ultrasound technology (described as “neurosurgery without a knife”) to help new disease-modifying medications penetrate the blood brain barrier. Watch here: https://lnkd.in/gk63BRqm
We can’t treat a condition that hasn’t been detected. And the latest stats on the under diagnosis of dementia, Alzheimer’s and MCI are abysmal.
We’re working hard to address barriers to detection in healthcare. We’ve made Neurotrack’s cognitive assessment platform flexible, frictionless, and fast, so that routine screening can become a standard of care for older adults.
We can catch issues early.
When you pair better detection with all of these exciting interventions becoming available, we will finally change the trajectory of cognitive disease.
